Xiaoyan Ni

653 citations
31 papers · 491 indexed · h-index 12
Topics
Hepatocellular Carcinoma Treatment and Prognosis (7 papers)Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers)Liver Disease Diagnosis and Treatment (5 papers)
Partner nations
ChinaUnited StatesCanada

In The Last Decade

Xiaoyan Ni

28 papers receiving 485 citations

Peers

Xiaoyan Ni
Comparison fields: 5 of 86
  • Molecular Biology 198
  • Oncology 82
  • Surgery 79
  • Reproductive Medicine 71
  • Cell Biology 59
Replace Yujuan Qi with:
Yujuan Qi China
H Ikegami Japan
Amber N. Hale United States
Robert E. Corin United States
María Celia Fernández Canada
Weipeng Xiong China
Vivek Dhir United Kingdom
Laura Mikkonen Finland
E. Okon Israel
Mukesh K. Jaiswal United States
Xiaoyan Ni relative to Yujuan Qi China Yujuan Qi's profile →
Citations per field
00.5×3.7×
Yujuan Qi · 1×
Citations per year

Countries citing papers authored by Xiaoyan Ni

Since Specialization
Citations

This map shows the geographic impact of Xiaoyan Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyan Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyan Ni more than expected).

Fields of papers citing papers by Xiaoyan Ni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyan Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyan Ni. The network helps show where Xiaoyan Ni may publish in the future.

Co-authorship network of co-authors of Xiaoyan Ni

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyan Ni. A scholar is included among the top collaborators of Xiaoyan Ni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyan Ni. Xiaoyan Ni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 2
4 10
5 2
6 5
7 3
8 4
9 7
10 4
11 5
12 29
13 11
14 31
15 18
16 11
17 46
18 87
19 5
20 24

About Xiaoyan Ni

Xiaoyan Ni is a scholar working on Hepatology, Cancer Research and Oncology, having authored 31 papers that have together received 491 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). The work is most often cited by research in Reproductive Medicine (71 citations), Physiology (27 citations) and Parasitology (27 citations). Xiaoyan Ni has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Carlos R. Morales, W. Scott Argraves, Guiliang Tang, Kuan‐Chun Huang, Shu‐Wing Ng, Ross S. Berkowitz, William R. Welch, Shu‐Kay Ng, Richard Oko and Dong Choon Park. Their work appears in journals such as PLoS ONE, Biochemical and Biophysical Research Communications and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026